Home/Filings/4/0000950170-24-027253
4//SEC Filing

Moran Kevin Patrick 4

Accession 0000950170-24-027253

CIK 0001347178other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 4:46 PM ET

Size

8.0 KB

Accession

0000950170-24-027253

Insider Transaction Report

Form 4
Period: 2024-03-04
Moran Kevin Patrick
SVP, CFO & Treasurer
Transactions
  • Sale

    Common Stock

    2024-03-05$4.20/sh8,902$37,411231,014 total
  • Sale

    Common Stock

    2024-03-04$4.48/sh5,798$25,982239,916 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    635
Footnotes (3)
  • [F1]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.435 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.195 to $4.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Documents

1 file

Issuer

Vanda Pharmaceuticals Inc.

CIK 0001347178

Entity typeother

Related Parties

1
  • filerCIK 0001806596

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:46 PM ET
Size
8.0 KB